Katarina Uttervall

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

REALiTEC: a multi-country observational retrospective study of teclistamab in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Journal: Haematologica

Published: September 30, 2025

Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden.

Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden.

Journal: Clinical hematology international

Published: July 24, 2025

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Journal: The New England journal of medicine

Published: December 09, 2024

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Journal: Cancers

Published: January 27, 2024

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.

Journal: Cancer medicine

Published: December 12, 2023

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma.

Journal: Cancer medicine

Published: June 12, 2023

Response to Caravita di Toritto and Rago.

Response to Caravita di Toritto and Rago.

Journal: European journal of haematology

Published: October 17, 2022

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

Conditioning with melphalan 200 mg/m2 and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care.

Journal: European journal of haematology

Published: May 25, 2022

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.

Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy.

Journal: American journal of hematology

Published: July 26, 2021

Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14).

Journal: American journal of hematology

Published: March 02, 2021

Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.

Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups.

Journal: European journal of haematology

Published: December 26, 2020

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?

Journal: European journal of haematology

Published: July 02, 2019

Showing 1-12 of 19

Last Updated: 09/26/2026